Biolinq Shine: Needle-Free Glucose Sensor Explained
· BiohackList Editorial
Disclaimer: This article is for information only and is not medical advice. Biolinq Shine, Dexcom Stelo and Abbott Lingo are not for people who use insulin and are not for diagnosing or treating diabetes or any other condition. Do not change medication, diet or exercise based on a sensor reading without talking to a qualified clinician. If you have symptoms of low or high blood sugar that concern you, seek medical care. Prices and availability change; Biolinq's US price and launch date were not announced as of our last check. BiohackList may earn commissions from qualifying purchases in the future.
Biolinq Shine is an FDA-cleared, needle-free forearm glucose sensor. It is designed to show glucose ranges with a color LED (and optional app detail), and it is cleared for adults 22+ who are not on insulin. It is not a dosing CGM and is not for acute medical decisions. Biolinq's Sep 24, 2026 press release describes the latest 510(k) as OTC; openFDA and biolinq.com do not use that word. Price, launch date, wear duration and public MARD were not announced as of Oct 5, 2026. Closest options you can buy today: Dexcom Stelo and Abbott Lingo.
In 30 seconds
- What it is: an FDA-cleared, needle-free forearm glucose sensor (company PR describes OTC; see regulatory section).
- What you see: a color LED meant to show in / above / below range (blue = in range on the brand site); an optional app adds trends with activity and sleep.
- Who it's for: adults 22+ who are not on insulin (Stelo and Lingo are cleared/intended for 18+).
- What it is not for: insulin dosing, medication adjustments or other acute medical decisions.
- Price and US on-sale date: not announced (as of Oct 5, 2026).
- Buyable alternatives today: Dexcom Stelo and Abbott Lingo.
What Biolinq Shine is
Biolinq Shine is a wearable patch designed to measure glucose with an array of microsensors and show range changes with a color LED on the device itself. Biolinq also puts activity and sleep sensing in the same patch (accelerometer and ambient light sensor) plus a companion app for more detail.
Biolinq's site calls it the "Biolinq Shine Autonomous Time-in-Range Microsensor" and says the qualitative display is meant "to aid in the management of a disease or condition related to glycemic control in persons 22 years or older not on insulin." It also states: "The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional."
Is Biolinq FDA-cleared?
Yes. Biolinq Shine is FDA-cleared, not "FDA approved" (approval language usually fits higher-risk pathways such as PMA). Per openFDA and Biolinq's Sep 24, 2026 announcement:
- De Novo classification DEN240080, decision date Sep 23, 2025.
- Traditional 510(k) clearance K262599, decision date Sep 18, 2026 ("Substantially Equivalent" on openFDA). Biolinq's Sep 24, 2026 press release describes it as OTC / without a prescription. openFDA's K262599 record and biolinq.com ("Now FDA cleared") do not say OTC.
- Class II, product code SFU, regulation 862.1359.
- openFDA device type name: Glucose Range Monitoring System.
- Device name on the FDA records: Biolinq Shine Autonomous Time-in-Range Microsensor.
- Applicant: Biolinq Incorporated (San Diego).
In plain terms: FDA classified the device type through De Novo, then cleared 510(k) K262599. That still does not make Shine a substitute for a prescription dosing CGM.
How it works without a needle
Biolinq and its clearance PR describe semiconductor-based microsensors that sit close to the skin's surface, without a hypodermic needle for placement. You wear the patch on the forearm.
The primary display is a color-coded LED on the patch, usable with or without a phone. On Biolinq's site, blue means target range and yellow means above range. The Sep 24 PR says the LED signals when glucose is within, above or below the target range. An optional app adds more detail and is meant to correlate glucose with meals, rest and activity. The same device tracks activity and sleep (accelerometer and ambient light sensor), per Biolinq.
Who it's for, and who should skip it
Cleared intended users (per Biolinq and its Sep 24, 2026 clearance PR): adults 22 years and older who are not on insulin. That age floor is higher than Stelo and Lingo (18+, not on insulin). Ages 18 to 21 are outside Shine's cleared range.
Skip Biolinq Shine (and talk to a clinician about other tools) if you use insulin or need numbers for dosing; need quantitative values for acute decisions; have concerning low or high blood sugar symptoms; or are under 22. Beyond Type 1's Sep 30, 2026 medically reviewed article makes the same point for insulin users: use a clinician-prescribed CGM instead.
For numeric readings you can buy today: Stelo (iCGM, 18+) or Lingo (CGM / glucose biosensor, 18+). Both exclude insulin users and are not for disease diagnosis.
Biolinq Shine vs a CGM (and vs Stelo and Lingo)
Biolinq is cleared as a Glucose Range Monitoring System. That is a different product type from an iCGM or a CGM that streams minute-by-minute mg/dL values to act on. Age limits also differ: Shine 22+; Stelo and Lingo 18+ (all three: not on insulin).
| Biolinq Shine | Dexcom Stelo | Abbott Lingo | |
|---|---|---|---|
| Official site | biolinq.com | stelo.com | hellolingo.com |
| BiohackList listing | Live: /listings/biolinq-shine | Live: /listings/dexcom-stelo | Live: /listings/abbott-lingo |
| Regulatory | De Novo DEN240080 (2025-09-23) + 510(k) K262599 (2026-09-18). Class II, SFU, Glucose Range Monitoring System. OTC = company PR only, not openFDA or biolinq.com | OTC iCGM (Stelo IFU) | OTC CGM / glucose biosensor (hellolingo.com) |
| Prescription | Company PR: no prescription (OTC claim) | No (OTC per brand) | No (OTC per brand) |
| Intended users | Adults 22+, not on insulin | People 18+, not on insulin | Users 18+, not on insulin |
| Insertion | Needle-free microsensors (brand / clearance PR) | Applicator inserts a small flexible wire under the skin | Applicator on the back of the upper arm |
| Wear site | Forearm | Arm | Back of upper arm |
| What you see | Color LED ranges on the patch; optional app. Not quantitative values for acute medical decisions | Numeric glucose values and trend in the Stelo app | Minute-by-minute numeric glucose in the Lingo app (up to 14 days*) |
| Also tracks | Activity + sleep in the same device | Lifestyle insights via app / coaching add-ons | App insights (food, exercise, Lingo Count) |
| Wear life | Not published | Up to 15 days* (stelo.com; brand cites a study where ~77.9% lasted the full 15 days) | Up to 14 days* (hellolingo.com; brand cites ~77.1% lasting the full 14 days) |
| Price (US, checked Oct 5, 2026) | Not announced | Buy page: plans starting at $84/month; a sensor option listed at $89 (was $99) | Homepage: Start Lingo for $54 (2-week / 1-biosensor, no commitment); 4-week subscription auto-renews at $84 every 4 weeks |
| Not for | Insulin dosing / medication adjustments / acute medical decisions; insulin users | Medical action without consulting a clinician; problematic hypoglycemia (Stelo important information) | Diagnosis of disease including diabetes; insulin users; problematic hypoglycemia (Lingo FAQ) |
* Wear-day figures are brand claims. Re-verify on publish day.
Recheck at publish: Stelo's $89 (was $99) and Lingo's $54 / $84-per-4-weeks plans had no stated end dates on Oct 5, 2026. Confirm on stelo.com/buy and hellolingo.com before publish.
Dexcom Stelo
Stelo is Dexcom's over-the-counter iCGM for people 18+ who are not on insulin. An applicator places a small sensor filament under the skin. The app shows numeric glucose. Wear is up to 15 days. Stelo says not to use it if you have problematic hypoglycemia, and to consult a clinician before medication changes based on sensor readings. On Oct 5, 2026, stelo.com/buy showed plans "starting at just $84/month," with a sensor option at $89 (was $99).
Abbott Lingo
Lingo is Abbott's over-the-counter glucose biosensor / CGM for users 18+ not on insulin. Abbott says it "is NOT intended for diagnosis of diseases, including diabetes," and not to use it with problematic hypoglycemia. The biosensor goes on the back of the upper arm and streams minute-by-minute glucose for up to 14 days. On Oct 5, 2026, hellolingo.com showed "Start Lingo today for just $54" (2-week / 1-biosensor, no commitment) and a 4-week subscription that auto-renews at $84 every 4 weeks. Site footnotes cite an Abbott study in which most surveyed users called application painless. That is a brand figure, not a BiohackList test.
Accuracy: what we know and don't know
We found no public MARD (mean absolute relative difference) or other accuracy number for Biolinq Shine on biolinq.com, in the Sep 24, 2026 clearance PR, or in Beyond Type 1's Sep 30, 2026 article. Until Biolinq or FDA publishes performance data, do not rank Shine vs Stelo or Lingo on accuracy.
Price, availability and what to watch for
As of Oct 5, 2026 (PT), US on-sale date, price and wear duration were not announced. Beyond Type 1 wrote that "Biolinq has yet to announce when Biolinq Shine will be available for purchase." Stelo and Lingo still have public US prices. Shine has a BiohackList listing; price and on-sale date were still not announced as of Oct 5, 2026.
Disclaimer: This article is for information only and is not medical advice. Biolinq Shine, Dexcom Stelo and Abbott Lingo are not for people who use insulin and are not for diagnosing or treating diabetes or any other condition. Do not change medication, diet or exercise based on a sensor reading without talking to a qualified clinician. If you have symptoms of low or high blood sugar that concern you, seek medical care. Prices and availability change; Biolinq's US price and launch date were not announced as of our last check. BiohackList may earn commissions from qualifying purchases in the future.
Affiliates are off for these products while drafting. See our affiliate disclosure. Listings and about: how listings are added.
How we researched this
We used Biolinq's US site, its Sep 24, 2026 GlobeNewswire PR (OTC claim in the headline), Beyond Type 1 (Sep 30, 2026), openFDA DEN240080 and K262599 (Oct 5, 2026), Stelo and Lingo official pages, and BiohackList listings for Shine, Stelo and Lingo. We have not tested these products. Update when Biolinq publishes price, launch, wear or accuracy data.
Last checked: Oct 5, 2026 (PT).
Sources
- Biolinq Shine product page (intended use; needle-free; LED ranges; activity and sleep) : https://www.biolinq.com/ (checked Oct 5, 2026)
- GlobeNewswire, "Biolinq Shine Receives FDA 510(k) Clearance for Over-the-Counter Use" (Sep 24, 2026) : https://www.globenewswire.com/news-release/2026/09/24/3368252/0/en/biolinq-shine-receives-fda-510-k-clearance-for-over-the-counter-use.html
- Beyond Type 1, Christine Fallabel (medically reviewed by Melanie Batchelor), "Can You Monitor Glucose Without A Needle Or A Prescription?" (Sep 30, 2026) : https://beyondtype1.org/biolinq-shine-fda-clearance/
- openFDA 510(k) DEN240080 (decision 2025-09-23) : https://api.fda.gov/device/510k.json?search=k_number:%22DEN240080%22
- openFDA 510(k) K262599 (decision 2026-09-18, Substantially Equivalent) : https://api.fda.gov/device/510k.json?search=k_number:%22K262599%22
- Dexcom Stelo : https://www.stelo.com/ and https://www.stelo.com/buy (checked Oct 5, 2026)
- Abbott Lingo : https://www.hellolingo.com/ (checked Oct 5, 2026)
- BiohackList, Biolinq Shine listing : https://www.biohacklist.com/listings/biolinq-shine
- BiohackList, Dexcom Stelo listing : https://www.biohacklist.com/listings/dexcom-stelo
- BiohackList, Abbott Lingo listing : https://www.biohacklist.com/listings/abbott-lingo
FAQ
What is Biolinq Shine?
Biolinq Shine is an FDA-cleared, needle-free forearm glucose sensor. A color LED on the patch is meant to show whether you are in, above or below a target glucose range, and an optional app adds more detail plus activity and sleep context.
Is Biolinq FDA approved or cleared?
It is FDA-cleared, not FDA-approved. Biolinq Shine received De Novo classification (DEN240080, Sep 23, 2025) and Traditional 510(k) clearance K262599 (decision Sep 18, 2026). The company's Sep 24, 2026 press release describes that clearance as over-the-counter; openFDA and biolinq.com do not use the word OTC.
How does Biolinq Shine work without a needle?
It uses semiconductor-based microsensors that sit just below the skin's surface, so placement does not use a hypodermic needle. You wear the patch on the forearm. A color LED is the primary display and works with or without a phone.
Who is Biolinq Shine for?
Adults 22 years and older who are not on insulin. It is meant for general awareness of glucose ranges and trends, not for insulin dosing or other acute medical decisions.
How is Biolinq Shine different from a CGM?
Biolinq is cleared as a Glucose Range Monitoring System. It shows ranges (and optional app detail), not quantitative glucose values for acute medical decision-making. Dexcom Stelo is an OTC iCGM and Abbott Lingo is marketed as an OTC CGM; both show numeric glucose in an app.
How accurate is Biolinq Shine?
We found no public MARD or other accuracy figure on biolinq.com, in the Sep 24, 2026 clearance PR, or in Beyond Type 1's Sep 30, 2026 coverage. Do not assume it matches Stelo or Lingo until Biolinq or FDA publishes numbers.
Can I buy Biolinq Shine yet, and what does it cost?
Not as of our Oct 5, 2026 check. Beyond Type 1 reported that Biolinq had yet to announce when Shine would be available for purchase. Price and wear duration were also not announced.
Do I need a prescription?
Biolinq's Sep 24, 2026 press release says the 510(k) clearance expands access without a prescription (OTC). openFDA records for K262599 and biolinq.com do not use the word OTC. Cleared intended users remain adults 22+ who are not on insulin.
Can people on insulin use Biolinq Shine?
No. It is cleared for adults who are not on insulin, and it is not intended for insulin dosing. People who use insulin need a clinician-prescribed CGM.
Biolinq Shine vs Dexcom Stelo vs Abbott Lingo?
Biolinq is needle-free and shows range colors on the patch. Stelo and Lingo use an applicator under the skin and show numeric glucose in an app. Stelo and Lingo are for sale now; Biolinq's price and US on-sale date were not announced as of Oct 5, 2026.
